Cherpillod C, Omer L M
J Int Med Res. 1981;9(5):324-9. doi: 10.1177/030006058100900505.
Diclofensine inhibits the uptake of serotonin, noradrenaline and dopamine. In a controlled study, out-patients suffering from moderate to severe depression were treated with the objective of assessing the new drug's therapeutically effective dose range. Maprotiline was used as a reference drug: fourteen patients were assigned to receive diclofensine and thirteen to receive maprotiline in a double-blind design. Depending on tolerance and efficacy, they were treated for periods ranging from 5 to 150 days. Doses were titrated to the optimum. Findings suggest that a 50 mg daily dose of diclofensine would be sufficient for the majority of the patients. The dosage can be safely increased up to 150 mg daily but this offers few therapeutic advantages. While the efficacy index of the two drugs was similar (approximately 60%), they differed greatly in their profile of side-effects. No signs of abrupt dissipation of the achieved clinical effects were observed during continued treatment, and no withdrawal reactions were observed when the treatment was stopped. The new drug may be more effective in treating patients in whom a psycho-energizing and mood alleviating effect is desired.
双氯芬辛抑制血清素、去甲肾上腺素和多巴胺的摄取。在一项对照研究中，对患有中度至重度抑郁症的门诊患者进行治疗，目的是评估这种新药的治疗有效剂量范围。马普替林用作参比药物：采用双盲设计，14名患者被分配接受双氯芬辛治疗，13名患者接受马普替林治疗。根据耐受性和疗效，他们接受了5至150天不等的治疗。剂量滴定至最佳水平。结果表明，每日50毫克的双氯芬辛剂量对大多数患者来说就足够了。剂量可安全增加至每日150毫克，但这几乎没有治疗优势。虽然两种药物的疗效指数相似（约60%），但它们的副作用情况差异很大。在持续治疗期间未观察到已取得的临床效果突然消失的迹象，停止治疗时也未观察到戒断反应。这种新药在治疗希望获得精神振奋和情绪缓解效果的患者时可能更有效。
